AZTR - Azitra Advances Targeted Dermatology Treatment with First Patient Dosed in ATR04-484 Trial

2025-08-27 08:53:44 ET

DENVER, Colo., Aug 27, 2025 ( 247marketnews.com )- Azitra (NYSE:AZTR) has taken a meaningful step forward in its mission to address one of oncology’s most common yet under-treated side effects: EGFR inhibitor (EGFRi)-associated rash. The company recently announced that the first patient has been dosed in its Phase 1/2 clinical trial of ATR04-484, a topically applied, live biotherapeutic candidate targeting this often-debilitating dermatologic toxicity.

The rash, which affects up to 80% of patients receiving EGFRis for cancers such as non-small cell lung cancer and colorectal cancer, can be severe enough to disrupt or halt life-saving treatment. Azitra’s approach aims to prevent that outcome through precision dermatology, using beneficial bacteria to modulate the skin’s response.

ATR04-484 incorporates a strain of Staphylococcus epidermidis engineered for both safety and targeted activity, designed to reduce key biomarkers like IL-36? and S. aureus , both elevated in EGFRi-related rash. The product is being tested in a multicenter, double-blind, vehicle-controlled study (NCT06830863) focused on safety, tolerability, and early signals of efficacy, including improvements in rash severity, pruritus, and pain.

With Fast Track designation from the FDA and a potential market of 150,000 affected patients annually in the U.S., ATR04-484 represents a novel approach to a persistent clinical challenge. As CEO Francisco Salva noted, the milestone “is an important step in the advancement of ATR04-484 and our broader ATR-04 technology program.”

In an era where targeted cancer therapies are increasingly common, effective management of their dermatologic side effects could significantly improve both patient outcomes and quality of life. Azitra’s progress could be the beginning of a long-overdue shift in how these rashes are treated, not just as side effects, but as conditions deserving of precision therapy in their own right.

The post Azitra Advances Targeted Dermatology Treatment with First Patient Dosed in ATR04-484 Trial appeared first on 24/7 MarketNews .

For further details see: